Tariffs
Commentary
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Commentary
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
Commentary
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
Commentary
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Commentary
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Business & Economics
Tariffs Either Can’t, Won’t, Or Shouldn’t Re-shore Manufacturing Jobs
Despite the unanimous ruling from the Court of International Trade, the Supreme Court will likely decide whether the International Emergency Economic Powers Act empowers President Trump to levy global tariffs. As this process will take time to play out, economic uncertainty will persist for the foreseeable future. What isn’t uncertain ...
Commentary
Potential Tariffs Will Harm Patients In The Name Of Protecting Them
Two months ago, the Commerce Department launched an investigation into whether pharmaceutical imports pose a threat to national security (i.e., a Section 232 investigation). Not only are the investigation’s accusations groundless, implementing the proposed remedy – more tariffs – will create the very problems that the investigation hopes to avoid. ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Blog
Why Your Next Bottle of French Champagne Could Cost More: Tariffs & US Sparkling Wine Options
When I read the news that prices on French Champagne could soon be soaring under President Trump’s tariff plan, my first response was to quickly get to my nearest Costco. Veuve Clicquot champagne, still made much like it was when first developed over 200 years ago by the “Grande Dame” ...
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Tariffs Either Can’t, Won’t, Or Shouldn’t Re-shore Manufacturing Jobs
Despite the unanimous ruling from the Court of International Trade, the Supreme Court will likely decide whether the International Emergency Economic Powers Act empowers President Trump to levy global tariffs. As this process will take time to play out, economic uncertainty will persist for the foreseeable future. What isn’t uncertain ...
Potential Tariffs Will Harm Patients In The Name Of Protecting Them
Two months ago, the Commerce Department launched an investigation into whether pharmaceutical imports pose a threat to national security (i.e., a Section 232 investigation). Not only are the investigation’s accusations groundless, implementing the proposed remedy – more tariffs – will create the very problems that the investigation hopes to avoid. ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Why Your Next Bottle of French Champagne Could Cost More: Tariffs & US Sparkling Wine Options
When I read the news that prices on French Champagne could soon be soaring under President Trump’s tariff plan, my first response was to quickly get to my nearest Costco. Veuve Clicquot champagne, still made much like it was when first developed over 200 years ago by the “Grande Dame” ...
